SCHEMBL922069

SCHEMBL922069

Nc1ccc2c(N)n[nH]c2c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 14/20 0.65
JAK2 O60674 4/20 0.64
KDM4E B2RXH2 2/20 0.56
CYP3A4 P08684 1/20 0.56
GAA P10253 1/20 0.56
AXL P30530 2/20 0.53
TGFBR1 P36897 5/20 0.49
AURKA O14965 4/20 0.49
AURKB Q96GD4 4/20 0.49
ROCK1 Q13464 2/20 0.49
CHUK O15111 1/20 0.49
RPS6KB1 P23443 1/20 0.49
CDK2 P24941 1/20 0.49
KDR P35968 1/20 0.49
SYK P43405 1/20 0.49
JAK3 P52333 1/20 0.49
MAP3K5 Q99683 1/20 0.49
FGFR1 P11362 1/20 0.46
FGFR2 P21802 1/20 0.46
MEN1 O00255 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL421269 0.84 JAK2 (0.77) PDPK1JAK2TGFBR1AURKAAURKB
SCHEMBL118573 0.82 JAK2 (0.64) PDPK1JAK2KDM4ECYP3A4GAA
SCHEMBL445902 0.81 FGFR1 (0.50) PDPK1JAK2KDM4EAXLAURKA
SCHEMBL30860966 0.81 PDPK1 (0.53) PDPK1JAK2KDM4EGAAAXL
SCHEMBL7571940 0.81 PDPK1 (0.53) PDPK1JAK2KDM4EGAAAXL
SCHEMBL14755254 0.81 AXL (0.49) PDPK1JAK2KDM4EGAAAXL
SCHEMBL588513 0.81 AXL (0.50) PDPK1JAK2KDM4EAXLTGFBR1
SCHEMBL2926172 0.81 AXL (0.49) PDPK1JAK2KDM4ECYP3A4GAA
SCHEMBL29613696 0.81 AXL (0.50) PDPK1JAK2KDM4EAXLTGFBR1
SCHEMBL2595141 0.81 AXL (0.49) PDPK1JAK2KDM4EGAAAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1926734-A1 PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS USEFUL AS KINASE ENZYMES MODULATORS Amgen Inc. (US) 2008-06-04 EP claimed
WO-2007024680-A1 PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS USEFUL AS KINASE ENZYMES MODULATORS AMGEN INC. (US) 2007-03-01 WO claimed
WO-2024178219-A1 1-ACYL-3-AMINOINDAZOLES FOR TREATING CYSTIC FIBROSIS SHOICHET BRIAN (US) 2024-08-29 WO disclosed
WO-2023039548-A1 KINASE INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER FRED HUTCHINSON CANCER CENTER (US) 2023-03-16 WO disclosed
WO-2022234271-A1 HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2022-11-10 WO disclosed
US-10668071-B2 (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-06-02 US disclosed
EP-3066100-B1 (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS Bayer Pharma AG (DE) 2019-04-17 EP disclosed
US-20180344739-A1 (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-12-06 US disclosed
US-10098883-B2 (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-10-16 US disclosed
US-20170239251-A1 (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-08-24 US disclosed
CN-104910148-B Aminotriazole(ATA) and pyridine and its as kinase inhibitor purposes 西格诺药品有限公司 2017-06-27 CN disclosed
EP-1926734-A1 PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS USEFUL AS KINASE ENZYMES MODULATORS Amgen Inc. (US) 2008-06-04 EP disclosed
US-20070232620-A1 3-Aminoindazoles MERCK PATENT GMBH (DE) 2007-10-04 US disclosed
US-20070232620-A1 3-Aminoindazoles MERCK PATENT GMBH (DE) 2007-10-04 US disclosed
US-20070232620-A1 3-Aminoindazoles MERCK PATENT GMBH (DE) 2007-10-04 US disclosed
US-20070219235-A1 Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors VTVX HOLDINGS I LLC 2007-09-20 US disclosed
WO-2007095124-A2 BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS AURORA KINASE INHIBITORS TRANSTECH PHARMA, INC. (US) 2007-08-23 WO disclosed
EP-1765788-A2 3-AMINOINDAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SGK-ASSOCIATED DISEASES MERCK PATENT GmbH (DE) 2007-03-28 EP disclosed
WO-2007024680-A1 PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS USEFUL AS KINASE ENZYMES MODULATORS AMGEN INC. (US) 2007-03-01 WO disclosed
WO-2005123688-A2 3-AMINOINDAZOLES MERCK PATENT GMBH (DE) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180344739-A1 (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE SERPINB6, SERPINC1, SERPINE1 PDPK1 1304/4885JAK2 167/4885KDM4E 2701/4885
US-10668071-B2 (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use SERPINB6, SERPINC1, SERPINE1 PDPK1 1304/4885JAK2 167/4885KDM4E 2701/4885
US-20170239251-A1 (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE SERPINB6, SERPINC1, SERPINE1 PDPK1 1304/4885JAK2 167/4885KDM4E 2701/4885
US-10098883-B2 (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use SERPINB6, SERPINC1, SERPINE1 PDPK1 1304/4885JAK2 167/4885KDM4E 2701/4885
US-20070219235-A1 Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors AURKC, AURKA, AURKB PDPK1 222/4885JAK2 634/4885KDM4E 769/4885
US-20070232620-A1 3-Aminoindazoles SGK3, SGK1, SGK2 PDPK1 118/4885JAK2 562/4885KDM4E 2491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.